Street Calls of the Week
In a challenging market environment, Halyard Health , Inc. (NYSE: NYSE:AVNS) stock has reached a 52-week low, dipping to $13.85. According to InvestingPro analysis, the company maintains a healthy financial position with a current ratio of 2.37, indicating strong liquidity. The stock currently appears undervalued based on InvestingPro’s Fair Value calculations. The healthcare company, known for its medical supplies and solutions, has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -29.18%. Investors are closely monitoring AVNS as it hits this critical price level, seeking signs of a potential turnaround or further indicators of market pressures that could influence the stock’s performance in the upcoming quarters. InvestingPro data reveals several positive indicators, including high shareholder yield and analysts’ expectations for profitability this year. Subscribers can access 8 additional ProTips and comprehensive analysis in the Pro Research Report, helping investors make more informed decisions during this critical period.
In other recent news, Avanos Medical (TASE:BLWV) reported its fourth-quarter 2024 financial results, surpassing analyst expectations. The company achieved earnings per share (EPS) of $0.43, exceeding the forecasted $0.40, and reported revenue of $179.6 million, higher than the anticipated $177.23 million. Additionally, Avanos completed the sale of its Respiratory Health business, marking a significant step in its ongoing transformation plan. The company has set a 2025 net sales guidance range of $665 million to $685 million, with an adjusted EPS guidance of $1.05 to $1.25. Avanos aims to focus on organic growth, particularly in its Specialty Nutrition Systems segment, and is targeting long-term gross margins of over 60%.
In leadership news, Avanos Medical announced the appointment of David Pacitti as its new CEO, effective April 14, 2025. Pacitti, transitioning from Siemens (ETR:SIEGn) Medical Solutions USA, brings extensive experience to the role. The company’s board expressed confidence in his ability to guide Avanos into its next growth phase. Avanos also continues to pursue strategic mergers and acquisitions, particularly in its Specialty Nutrition Systems segment, to align with its transformation priorities. These developments reflect Avanos Medical’s strategic focus on enhancing its market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.